Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202....

Descripción completa

Detalles Bibliográficos
Autores principales: Steinhardt, Maximilian Johannes, Zhou, Xiang, Krummenast, Franziska, Meckel, Katharina, Nickel, Katharina, Böckle, David, Messerschmidt, Janin, Knorz, Sebastian, Dierks, Alexander, Heidemeier, Anke, Lapa, Constantin, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768838/
https://www.ncbi.nlm.nih.gov/pubmed/33353443
http://dx.doi.org/10.1177/2058738420980258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768838/
https://www.ncbi.nlm.nih.gov/pubmed/33353443
http://dx.doi.org/10.1177/2058738420980258

Ejemplares similares